PDE3B and metabolic syndrome: The association of PDE3B pLOFs with improved body fat distribution, reduced risk of hypercholesterolemia and reduced risk of coronary artery disease suggests that selective inhibition of PDE3B may be useful for multiple features of metabolic syndrome.